



LIFTMODE
47 W. Polk St. STE 100-241
Chicago, IL 60605

liftmode@liftmode.com
liftmode.com

CERTIFICATE OF ANALYSIS

LibidoLift

Material Lot #: 201832
Country of Origin: USA

Analysis Date: 11/18/2020
Retesting Date: 11/18/2023

Analysis	Claim	Result
Capsule Weight	≥350mg	380mg

Ingredient	Specification	Result
Vitamin D	14,600mcg/100g	14,600mcg/100g
Zinc	1,143mg/100g	1140mg/100g
Selenium	154,285mcg/100g	155,000mg/100g
Acteoside	≥5.49%	5.99%
Eurycomanone	≥2.4%	2.82%
Ginsenosides	≥5.14%	6.21%

ICP-MS		
Arsenic	≤1.5 ppm	0.194 ppm
Lead	≤0.5 ppm	0.151 ppm
Cadmium	≤0.5 ppm	0.026 ppm
Mercury	≤0.5 ppm	<0.001 ppm

Total Aerobic Count	<1000 cfu/g	Conforms
Yeast & Mold	<100 cfu/g	Conforms
Coliform	<10 cfu/g	Conforms
<i>E.coli</i>	Negative	Conforms
Salmonella	Negative	Conforms

LibidoLift should be stored at or below room temperature in a tightly sealed durable container.
LibidoLift should be protected from excess heat, direct sunlight, excess humidity, and moisture.
LibidoLift has a retesting period of 3 years from the date of analysis when properly stored.



Medallion Labs

www.medallionlabs.com 800-245-5615 info@medlabs.com

Order # Sample ID: 2020-010107-01 **Company:** Synaptent LLC
Customer Sample ID: 201832
Sample Description: LibidoLift 201832

Analytical Testing

<u>Method:</u>	<u>Component:</u>	<u>Result:</u>	<u>Test Date:</u>
Metals (ICP-MS)	Selenium	155000 ppb	10-Nov-2020
Metals (ICP-OES)	Zinc	1140 mg/100g	13-Nov-2020
^{1 2} Vitamin D	Vitamin D2	<0.00100 mcg/g	25-Nov-2020
	Vitamin D3	14600 mcg/100g	25-Nov-2020

Results Approved By: Jamie Reese
(Authorized Reviewer)

Medallion Labs maintains A2LA accreditation to ISO/IEC 17025 for the specific tests listed in certificates # 2769.01 and 2769.02. Medallion Labs' services, including this report, are provided subject to all provisions of Medallion's Standard Terms and Conditions, a copy of which appears at www.medallionlabs.com. Unless otherwise noted above, samples were received in acceptable condition and analyzed as received.

¹ This analysis is performed by a partner lab.

² This test is not considered in-scope of our current A2LA accreditation. For a listing of in-scope tests, please visit www.medallionlabs.com.

CERTIFICATE OF ANALYSIS




12661 HOOVER STREET GARDEN GROVE, CA 92841 | P. 714-754-4372 | F. 714-668-9972 | WWW.ALKEMIST.COM

Report Issued To: Synaptent
47 W. Polk St.
Chicago Illinois 60605

Sample Name: LibidoLift
Description: Powdered extract; Fine Light Brown Powder
Lot #: 201832
AL #: 20310UKN_3
Analysis ID: 146496
Received: 11/05/20

Determination of Acteoside Content by HPLC



Ret. Time (min)	Compound Name	Prep 1 (%)	Prep 2 (%)	Average (%) As Is	Average (%) Dried Basis	Specification	Result
26.9	Acteoside	6.201	5.382	5.791	5.985	Report Only	N/A

Chromatographic Conditions:

Method: EP 10.1 0 Lemon Verbena Leaf
Column: AP119 Luna C18(2) 5µm (250 x 4.0 mm)
Temperature: 20°C
Flow Rate: 1 mL/min
Injection Volume: 20 µL
UV Detection: 330 nm
Mobile Phase: 0.3% Phosphoric Acid
Acetonitrile
HPLC Instrument: Alliance_4

Sample Preparation:

Mixed sample well and transferred 500 mg to an erlenmeyer flask. Added 25.0 mL of 60% ethanol. Mixed with a magnetic stirrer for 2 hours. Centrifuged for 10 minutes. Diluted 1:10 in 60% ethanol. Filtered into vials for analysis.

Report Summary:

Conclusion: This "LibidoLift" test sample contains an average of 6.0% acteoside on the dry basis.
OOS Reference: N/A
Loss on Drying: 3.24%
Note: This method has not been validated for this sample matrix.
Notebook Reference: 33920 Acteoside



Celine Deneuve
Senior Analytical Chemist

Digitally signed by Celine Deneuve
DN: cn=Celine Deneuve, o, ou, email=celine@alkemist.com, c=US
Date: 2020.12.07 16:26:27 -08'00'

Analysis Date : 12/07/20 Analyzed By: M Edwards

**Authorized By: Celine Deneuve,
Analytical Chemistry Supervisor**

CERTIFICATE OF ANALYSIS




12661 HOOVER STREET GARDEN GROVE, CA 92841 | P. 714-754-4372 | F. 714-668-9972 | WWW.ALKEMIST.COM

Report Issued To: Synaptent
47 W. Polk St.
Chicago Illinois 60605

Sample Name: LibidoLift
Description: Powdered extract; Fine Light Brown Powder
Lot #: 201832
AL #: 20310UKN_1
Analysis ID: 146490
Received: 11/05/20

Determination of Eurycomanone Content by HPLC



Ret. Time (min)	Compound Name	Prep 1 (%)	Prep 2 (%)	Average (%)	Specification	Result
5.1	Eurycomanone	2.839	2.797	2.818	Report Only	N/A

Chromatographic Conditions:

Method: ATM-815-0222
Column: AP22 Luna 5 μ C18 (2) (150 x 4.6 mm)
Temperature: 40°C
Flow Rate: 1 mL/min
Injection Volume: 20 μ L
UV Detection: 254 nm
Mobile Phase: 0.1% Formic Acid in Water
Acetonitrile
HPLC Instrument: Alliance_1

Sample Preparation:

Weighed 250 mg sample into 10 mL volumetric flask and filled to volume with methanol. Vortexed for 30 seconds and sonicated for 15 minutes at room temperature. Let cool and filled to volume with methanol. Mixed by inversion. Diluted 1:50 in methanol. Filtered through 0.45 μ m PTFE syringe filter into HPLC vial for analysis.

Report Summary:

Conclusion: This "LibidoLift" test sample contains an average of 2.8% Eurycomanone on the as is basis.
OOS Reference: N/A
WI Reference: 33920 Eurycomanone

Digitally signed by Celine Deneuve
DN: cn=Celine Deneuve,
o, ou,
email=celine@alkemist.com, c=US
Date: 2020.12.07 16:25:10 -08'00'



Analysis Date : 12/07/20 **Analyzed By:** T French

Authorized By: Celine Deneuve,
Analytical Chemistry Supervisor

CERTIFICATE OF ANALYSIS




12661 HOOVER STREET GARDEN GROVE, CA 92841 | P. 714-754-4372 | F. 714-668-9972 | WWW.ALKEMIST.COM

Report Issued To: Synaptent
47 W. Polk St.
Chicago Illinois 60605

Sample Name: LibidoLift
Description: Powdered extract; Fine Light Brown Powder
Lot #: 201832
AL #: 20310UKN_2
Analysis ID: 146033
Received: 11/05/20

Determination of Ginsenosides Content by HPLC



Ret. Time (min)	Compound Name	Prep 1 (%)	Prep 2 (%)	Average (%)	Average Dried Basis (%)	Specification	Result
18.9	Rg1	1.701	1.618	1.660	1.744	N/A	N/A
19.6	Re	1.471	1.394	1.432	1.505	N/A	N/A
39.2	Rb 1	1.260	1.187	1.223	1.285	N/A	N/A
41.3	Rc	0.227	0.213	0.220	0.231	N/A	N/A
43.5	Rb 2	0.371	0.351	0.361	0.379	N/A	N/A
48.1	Rd	1.051	0.974	1.012	1.064	N/A	N/A
	Total Ginsenosides	6.081	5.737	5.909	6.208	Report Only	N/A

Chromatographic Conditions:

Method: USP 42 - Powdered Asian Ginseng Extract
Column: AP144 Gemini 3 μ C18 110A (150 x 4.6 mm)
Temperature: 25°C
Flow Rate: 1.5 mL/min
Injection Volume: 20 μ L
UV Detection: 203 nm
Mobile Phase: Water
Acetonitrile:Water (4:1; v/v)
HPLC Instrument: Alliance_3

Sample Preparation:

Mixed sample well and transferred approximately 240 mg of sample to 10 mL volumetric flask, filled to volume with 40% ethanol and vortexed for 30 seconds. Sonicated 10 minutes at room temperature. Filtered through a 0.45 μ m PTFE syringe filter into HPLC vial.

Report Summary:

Conclusion: This "LibidoLift" test sample contains an average of 6.2% total ginsenosides as Rg1, Re, Rb1, Rc, Rb2 and Rd on the anhydrous basis.
OOS Reference: N/A
Water Content: 4.82%
Notebook Reference: LC154 p. 001



Celine Deneuve
Senior Analytical Chemist

Digitally signed by Celine Deneuve
DN: cn=Celine Deneuve, o, ou, email=celine@alkemist.com, c=US
Date: 2020.11.25 10:04:13 -08'00'

Analysis Date : 11/24/20 Analyzed By: T French

**Authorized By: Celine Deneuve,
Analytical Chemistry Supervisor**



Certificate of Analysis


Client:


Synaptent LLC
 47 W Polk Street, 100-241
 Chicago, IL 60654

Sample Collected By: Client

Product Name	Libido Lift	Product Lot Number	201832
Report Date	11/18/20	Laboratory Number	20111363

Description	Method	Specification	Results
Lead	ICP-MS	<0.5 ppm	0.151 ppm
Arsenic	ICP-MS	<0.5 ppm	0.194 ppm
Cadmium	ICP-MS	<0.5 ppm	0.026 ppm
Mercury	ICP-MS	<0.5 ppm	<0.001 ppm
Total Aerobic Count	Biolumix	<1, 000 cfu/g	<1, 000 cfu/g
Yeast & Mold	Biolumix	<100 cfu/g	<100 cfu/g
E. Coli	Biolumix	Negative	Negative
Coliform	Biolumix	<10 cfu/g	< 10 cfu/g
Salmonella	Biolumix	Negative	Negative

Collin Thomas 
 Laboratory Manager

11/18/2020 
 Date

The result(s) stated in this report is only for the sample submitted. This report may not be reproduced in whole or in part, nor may any reference be made to the work, the result, or the company in any news release, public announcements or advertising without our prior written consent.